USFDA completes inspection at Granules India’s Hyderabad facility

09 Sep 2024 Evaluate

US Food and Drug Administration (USFDA) has completed inspection at Granules India’s Gagillapur facility in Hyderabad, Telangana. The inspection, conducted from August 26, 2024 to September 06, 2024, concluded with six observations.

The recent inspection covered both Current Good Manufacturing Practice (cGMP) and Pre-Approval Inspection (PAI) processes. Granules India is committed to addressing the observations promptly and will submit its response to the USFDA within the stipulated timeframe. The Gagillapur facility continues to play a vital role in the company’s global operations, ensuring the supply of high-quality pharmaceutical products to markets worldwide.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

598.30 1.05 (0.18%)
23-Feb-2026 15:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1731.05
Dr. Reddys Lab 1307.45
Cipla 1326.55
Zydus Lifesciences 907.85
Lupin 2243.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×